Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

Orion S.A.: board member Michel Wurth will not stand for re-election

Orion S.A. said in an SEC filing that board member Michel Wurth will not run again at the 2026 annual general meeting. Wurth cited increasing commitments from other activities as the reason for his withdrawal and stressed that this was not due to disagreements with the company or the board of directors. » More on de.investing.com
Orion to close several carbon black production lines by 2025 and announces dividend

Orion S.A. will shut down three to five carbon black production lines at sites in the Americas and EMEA by the end of 2025, aiming to focus on higher-performing facilities and improve free cash flow. The company cites economic uncertainties, recent US tariffs, and an EU anti-dumping investigation as reasons for the move. Additionally, Orion has announced an interim dividend for the fourth quarter of 2025, while JPMorgan analysts have downgraded the stock. » More on de.investing.com
Orion S.A. announces interim dividend despite share price decline and analyst downgrade

Orion S.A. will distribute an interim dividend of $0.0207 per share in both the third and fourth quarters of 2025, despite a 34% drop in its share price over the past six months. Analysts at JPMorgan have downgraded the stock from Overweight to Neutral and lowered the price target, citing economic uncertainties, but highlight the company's strong free cash flow yield projected for 2026. The dividends are subject to a 15% Luxembourg withholding tax, with possible reductions under certain conditions. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2026, Orion A has already paid €0.90 in dividends. The last payout was in April.

Financials

In the last quarter, Orion A had revenue of €521.6M and net profit of €140.2M

(EUR)	June 2026	YoY
Revenue	521.6M	25.23%
Gross profit	339.9M	36.84%
Net profit	140.2M	69.94%
EBITDA	194.1M	85.39%

Fundamentals

Metric	Value
Market capitalization	€12.96B
Number of shares	141.13M
52-week high/low	€92.30 - €56.30
Dividend yield	0.98%
Dividends TTM	€0.90
Next dividend	€0.90
Beta	0.29
P/E ratio	22.13
PEG ratio	0.40
P/B ratio	10.25
P/S ratio	6.30

Company profile

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, other European countries, North America, and internationally. It provides prescription drugs and self-care products, including Nubeqa for the treatment of prostate cancer; dexdor and Precedex for intensive care sedative; Stalevo and Comtess/Comtan for Parkinson's disease; Simdax for acute decompensated heart failure; and Fareston for breast cancer, as well as Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. The company also offers veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; and APIs for generic and proprietary drugs, as well as provides contract manufacturing services. In addition, it markets and sells veterinary drugs manufactured by other international companies. The company serves various healthcare service providers and professionals, such as specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centers, clinics, and laboratories, as well as consumers with pets. Orion Oyj has partnership with Propeller Health to connect the Easyhaler(R) product portfolio for the treatment of asthma and COPD; and a research collaboration and license agreement with Alligator Bioscience AB (publ) to discover and develop new bispecific antibody cancer therapeutics. Orion Oyj was founded in 1917 and is headquartered in Espoo, Finland.